
SEARCH HOME		ADVANCED SEARCH		RSS FEED

Search Results - Oncology

21 Results

Sort By:

Anti-LILRB5 Monoclonal Antibodies for Therapeutic and Diagnostic Use

Tumor microenvironment (TME) plays a critical role in regulating immune responses to tumors. UTHealth Houston and UTSW researchers discovered certain membrane tyrosine kinase Eph receptors, including EphA7 and EphB1, specifically bind to the immune inhibitory receptors leukocyte Ig-like receptor family B 5 (LILRB5) and result in bi-directional signaling....

Published: 2/16/2026 | Inventor(s):

Keywords(s):

Category(s): Diagnostics, Therapeutics, Oncology

Anti-LILRB1 Monoclonal Antibodies for Therapeutic and Diagnostic Use

LILRB1 expression on myeloid cells regulates both innate and adaptive immune responses. Researchers at UTHealth Houston and UTSW developed novel agonistic anti-LILRB1 monoclonal antibodies (mAbs) for autoimmune and inflammatory disease treatments, and novel antagonistic anti-LILRB1 mAbs for cancer immunotherapies. Background LILRB1, a member of the...

Published: 2/16/2026 | Inventor(s):

Keywords(s):

Category(s): Diagnostics, Therapeutics, Oncology

Anti-LAIR1 Monoclonal Antibodies for Therapeutic and Diagnostic Use

Leukocyte associated immunoglobulin like receptor 1 (LAIR1 or CD305) is an immune inhibitory receptor expressing on most immune cell types. Researchers at UTHealth Houston and UTSW generated novel antagonistic anti-LAIR1 monoclonal antibodies (mAbs) that inhibited the activity of immunosuppressive myeloid cells and reactivated T cells from cancer patients...

Published: 2/16/2026 | Inventor(s):

Keywords(s):

Category(s): Diagnostics, Therapeutics, Oncology

Anti-LILRB3 Monoclonal Antibodies for Therapeutic and Diagnostic Use

UTHealth Houston and UTSW researchers discovered that LILRB3 stimulates NF-κB signaling and enhances acute myeloid leukemia (AML) cells. They generated a panel of novel anti-LILRB3 monoclonal antibodies (mAbs), which exhibited increasing killing of leukemia cells and promoting cytotoxic T cell activity against tumors. Background Leukocyte immunoglobulin-like...

Published: 2/16/2026 | Inventor(s):

Keywords(s):

Category(s): Diagnostics, Oncology, Therapeutics

CAR-T Cells Targeting LILRB4 for Therapeutic and Diagnostic Use

CAR-T cell therapy development for AML has been limited by lack of an antigen with high specificity for AML cells that is not present on normal hematopoietic stem cells. UTHealth Houston and UTSW researchers discovered that leukocyte immunoglobulin-like receptor-B4 (LILRB4) is a tumor-associated antigen highly expressed on monocytic AML cells. They...

Published: 2/16/2026 | Inventor(s):

Keywords(s):

Category(s): Cell Therapies, Biologics, Oncology, Therapeutics

SLC13A3 Monoclonal Antibody for Therapeutic and Diagnostic Use

Description: SLC13A3 is revealed here, for the first time based on our evaluation, as a transporter for itaconate in tumor cells which plays a role in promoting tumor ferroptosis resistance, thereby weakening tumor immunity and immune checkpoint blockade (ICB). World renowned immuno-oncology leaders from UTHealth and University of Michigan (UMich)...

Published: 1/15/2026 | Inventor(s):

Keywords(s):

Category(s): Therapeutics, Oncology

EGFL6 Specific Monoclonal Antibodies for Cancer Diagnostic and Therapeutic Use

Human epidermal growth factor (EGF)-like domain multiple 6 (EGFL6) was discovered in tumors and fetal tissues. Upregulated expression of EGFL6 was found in a variety of cancer cell types, such as ovarian cancer and lung cancer. Unlike VEGF, which was expressed in ovarian cancer tissues and in healing wounds, EGFL6 was expressed mainly in tumor-associated...

Published: 1/15/2026 | Inventor(s): Zhiqiang An, Anil Sood, Ningyan Zhang

Keywords(s):

Category(s): Biologics, Therapeutics, Oncology

S100A4 Monoclonal Antibody for Therapeutic and Diagnostic Use

Cancer metastasis are responsible for ~90% of cancer associated deaths. Recent studies suggest that immune cells play critical roles in promoting metastasis, especially myeloid cells from the bone marrow. UTHealth researchers, with researchers from Houston Methodist Hospital, observed a highly conserved expression of S100A4 in immune suppressive myeloid...

Published: 1/15/2026 | Inventor(s): Zhiqiang An, Ningyan Zhang

Keywords(s):

Category(s): Neurology/Neurosurgery, Oncology, Therapeutics

Monoclonal Antibodies Against PCDH7 for Therapeutic and Diagnostic Use

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-associated deaths worldwide. UTHealth researchers discovered that the cell surface protein Protocadherin 7 (PCDH7) is highly expressed in NSCLC and promotes lung cancer development. Inventors at UTH in collaboration with Dr. O’Donnell’s group at UTSW have discovered a panel...

Published: 1/15/2026 | Inventor(s): Zhiqiang An, Ningyan Zhang, Kathryn O'Donnell

Keywords(s):

Category(s): Diagnostics, Oncology, Therapeutics, Biologics

Monoclonal antibodies against human endotrophin for therapeutic and diagnostic use.

Background Studies have shown that endotrophin, the carboxy-terminal cleavage product of the COL6α3 chain, has potent effects on transformed mammary ductal epithelial cells in rodents. It is abundantly expressed in adipose tissue and is a chemoattractant for macrophages, exerts effects on endothelial cells and enhances the progression through...

Published: 1/15/2026 | Inventor(s): Zhiqiang An, Ningyan Zhang, Philipp Scherer

Keywords(s):

Category(s): Biologics, Oncology, Therapeutics

1 2 3

|

|

© 2026. All Rights Reserved. Powered by Inteum